In this study, we demonstrate the capacity of antibody-based therapy to eliminate a subpopulation of CD8+ T cells expressing SLAMF7 using in vivo data from MM patients as well as in vitro assays and an in vivo murine model. The gene discussed is CD8A; the disease is Miyoshi myopathy.